Skip to main content

Table 3 Summary of drug costs in Republic of Korea

From: The value measurement of emerging therapeutics in renal cell carcinoma: ASCO value framework and ESMO-MCBS

Treatment

Total cost (dollar/4 week)

Pazopanib 800 mg qd

12,768

Nivolumab 3 m/Kg, D1 + Ipilimumab 1 mg/Kg, D1

Q2weeks for 3 months

Followed by nivolumab only

39,584 (for 3 months)

➔ 10,544

Axitinib 5 mg qd + Avelumab 10 mg/Kg D1

Q3weeks

58,460

Axitinib 5 mg qd + Pembrolizumab 200 mg D1

Q3weeks

59,709

Lenvatinib 20 mg qd + Pembrolizumab 200 mg D1

Q3weeks

93,005

Cabozantinib 40 mg qd + Nivolumab 240 mg D1

Q2weeks

26,616

  1. The drug costs for RCC were summarized
  2. Body weight: 60 kg